Table 2.
Characteristics of post-transplant lymphoproliferative disorders in the 52 patients who underwent retransplantation
| Characteristics | n (%) |
|---|---|
| PTLD localization (%) | |
| Unique localization | 33 (64) |
| Multiple localizations | 19 (36) |
| Main localization (%) | |
| Graft | 18 (35) |
| Lymph nodes/bone marrow | 17 (33) |
| Gastrointestinal tract | 7 (13) |
| Ear, nose, and throat | 4 (8) |
| Central nervous system | 4 (8) |
| Other sites | 2 (3) |
| EBV status (%) | |
| EBV-positive PTLD | 27 (67) |
| EBV-negative PTLD | 13 (33) |
| Unknown | 12 |
| World Health Organization classification (%) | |
| Early B lesions | 3 (7) |
| Polymorphic B PTLD | 5 (12) |
| Monomorphic PTLD | 33 (78) |
| B cell neoplasms | 30 |
| T cell neoplasms | 3 |
| Classic Hodgkin lymphoma | 1 (2) |
| Unknown | 10 |
PTLD, post-transplant lymphoproliferative disorder; EBV, Epstein–Barr virus.